I calculated the equivalent price per share of the $147,000
I calculated the equivalent price per share of the $147,000 plus interest and penalties to equate to less than $0.02/share if QMC had defaulted and L2 used the conversion rules.
Just think how 9 million shares with a price point less than 2 cents would affect the share price. We would like hit new lows.
I'm glad Steve is doing what he needs to do to prove he did not default and to fight these guys in court.
Now, Steve, just issue the 10k!!!
1
Quantum Materials Corp. (QTMM) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Adobe's Options Activity Highlights In the world of finance, significant trades often signal important market sentiments. Recently, major investors have moved toward a bearish outlook on Adobe. Analyzing the options history for Adobe (NASDAQ: ADBE), we've identified a total of 67 significant trades. Our insights reveal that approximately 41% of these trades have been...
Continue Reading
Indonesia's Maritime Security Efforts Intensify Recently, Indonesia's maritime security has been under increased scrutiny as incidents involving a Chinese coast guard vessel continue to escalate. This week, a Chinese vessel was driven from Indonesian waters not once, but twice, after interfering with a critical energy survey conducted by Pertamina, the state energy...
Continue Reading
Welcome to the Future of Game Development Upheaval Games, founded by veterans from the gaming industry, embraces a new frontier in game design with the introduction of The Dreamer Portal. This innovative web-based interface allows creators to effortlessly build immersive game content with just a simple prompt. Imagine the power of crafting unique creatures, items, and...
Continue Reading
Alvotech and Advanz Pharma Collaborate for Biosimilar Approval REYKJAVIK and LONDON – Alvotech (NASDAQ: ALVO), a renowned biotechnology firm, along with Advanz Pharma, a leading global pharmaceutical company, has shared important news regarding the marketing approval of Gobivaz®, a proposed biosimilar to Simponi® (golimumab). This biologic treatment is designed for...
Continue Reading
Remote Patient Monitoring Set for Dynamic Growth The increasing prevalence of chronic conditions worldwide is expected to significantly accelerate the growth of the remote patient monitoring (RPM) market. As conditions like hypertension, diabetes, and cardiovascular diseases become more common, coupled with an aging population, healthcare systems face immense pressure to...
Continue Reading